Journal
NUTRIENTS
Volume 11, Issue 8, Pages -Publisher
MDPI
DOI: 10.3390/nu11081926
Keywords
GSH; cancer therapy; ferroptosis; synthetic lethality
Categories
Funding
- Italian Association for Cancer Research (AIRC) [IG 15403]
- MIUR/PRIN 2017 [2017A5TXC3]
- European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant [800924]
Ask authors/readers for more resources
Glutathione (GSH) is the predominant low-molecular-weight antioxidant with a ubiquitous distribution inside the cell. The steady-state level of cellular GSH is dependent on the balance between synthesis, hydrolysis, recycling of glutathione disulphide (GSSG) as well as cellular extrusion of reduced, oxidized, or conjugated-forms. The augmented oxidative stress typical of cancer cells is accompanied by an increase of glutathione levels that confers them growth advantage and resistance to a number of chemotherapeutic agents. Targeting glutathione metabolism has been widely investigated for cancer treatment although GSH depletion as single therapeutic strategy has resulted largely ineffective if compared with combinatorial approaches. In this review, we circumstantiate the role of glutathione in tumour development and progression focusing on how interfering with different steps of glutathione metabolism can be exploited for therapeutic purposes. A dedicated section on synthetic lethal interactions with GSH modulators will highlight the promising option of harnessing glutathione metabolism for patient-directed therapy in cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available